There is no retatrutide price in Australia. Not a private one, not a PBS one, not an indicative one — because the drug is still investigational, hasn't been approved by the TGA, and Eli Lilly's own filing plans point to a first regulatory submission in the United States in early 2027. So anyone quoting you a "retatrutide cost Australia" figure for a pharmacy medicine is quoting a number that doesn't exist yet.

What does exist is a set of very recent, very specific Australian decisions about what this country is willing to pay for obesity drugs. Two of them landed in 2026, weeks apart, and they went in opposite directions. If you want to understand what retatrutide will cost Australians, those two decisions are the most informative material available today — far more so than any price list.

Retatrutide price in Australia: why there isn't one

Retatrutide is Lilly's triple agonist, acting on GLP-1, GIP and glucagon receptors — one more target than tirzepatide (Mounjaro/Zepbound) and two more than semaglutide (Ozempic/Wegovy). You can read the mechanism in plain English on what is retatrutide and the phase 3 data on our clinical trials page, where TRIUMPH-1 reported up to about 28.3% average body weight loss at 12mg over 80 weeks.

None of that changes the regulatory position. Reporting through 2026 confirms retatrutide has no marketing authorisation in the US, UK or EU, and Lilly has signalled a first-quarter 2027 submission to the FDA. The TGA works from a sponsor's application; no application, no price. For the Australian sequence in detail, see our Australia page.

Precedent one: Lilly walked away from the PBS in April 2026

This is the single most important Australian pricing event of the year, and it barely registered outside the trade press.

After rejecting three earlier applications, the Pharmaceutical Benefits Advisory Committee recommended tirzepatide for PBS listing for adults with inadequately controlled type 2 diabetes at its March 2026 meeting. Then Lilly said no. Its general manager for Australia and New Zealand described the price the government was willing to pay as significantly lower than any other reimbursed price globally, and the company declined the listing — leaving roughly 450,000 Australians with type 2 diabetes without a subsidised option, as the ABC reported.

Lilly went further. On the back of that outcome, the company said it was difficult to see how a PBS listing for Mounjaro could be secured for Australians living with obesity or obesity-related disease.

That is Lilly, on the record, about its own current incretin drug, in this market. It is the closest thing to a signal about how retatrutide reimbursement negotiations might go — and it's a signal about the pricing system, not about retatrutide specifically.

Precedent two: Wegovy's PBS "yes" was real, but narrow

The other direction: in January 2026 the PBAC recommended Wegovy (semaglutide 2.4mg) for PBS listing, with the Health Minister committing to subsidy for patients with established cardiovascular disease and a BMI of 35 or above, subject to price negotiation with Novo Nordisk.

Two things are worth holding onto there. First, subsidy for a weight-loss drug in Australia is no longer hypothetical. Second, the gate is tight: cardiovascular disease plus severe obesity, not obesity alone. With roughly 66.8% of Australian adults living with overweight or obesity, a criterion like that reaches a small slice of the affected population.

What Australians are actually paying now

Until something is subsidised, the private market is the reference point. Reporting around the Wegovy decision put the picture bluntly: more than 400,000 Australians are paying market prices for GLP-1s, at as much as $4,000 to $5,000 a year, with monthly private costs in the several-hundred-dollar range. PBS-subsidised patients, by contrast, pay a standard co-payment per script — a small fraction of that, and less again with a concession card.

That gap between private price and co-payment is the whole game for any future retatrutide launch here. It isn't decided by trial results.

The exclusivity fight sitting underneath the price

There's a second layer, and it's live right now. Lilly and the FDA disagree about whether retatrutide is a biologic. The FDA has determined it is not, which would route it through a New Drug Application with five years of market exclusivity; Lilly argues it is a biologic, which would mean a Biologics License Application and 12 years. Lilly appealed to the Seventh Circuit, with oral argument set for 24 September 2026, according to BioSpace's reporting.

Classification also shapes what competition looks like later — copycats of a biologic must clear the more demanding biosimilar pathway rather than a conventional generic route. Long-run competition is one of the things that eventually pulls prices down anywhere, including here. We're reporting the dispute, not predicting its outcome or any resulting price.

What to actually do with this

Nothing about retatrutide is purchasable as an approved Australian medicine today, so there is no budget to build. The useful moves are unglamorous: understand the side effect and safety profile that will govern who's eligible if it is approved, follow the TGA submission step rather than overseas headlines, and watch whether the PBAC/pricing impasse that killed the tirzepatide diabetes listing gets resolved — because that mechanism, not the molecule, will decide affordability.

Join our free updates list and we'll email you when there's an actual Australian regulatory or pricing development to report.

FAQ

How much will retatrutide cost in Australia?

No price exists. Retatrutide isn't TGA-approved and no Australian price has been set, so any specific dollar figure circulating for it as a pharmacy medicine is not based on a real listing. For scale, privately paid GLP-1 treatment in Australia has been reported at as much as $4,000–$5,000 a year.

Will retatrutide be on the PBS?

Unknown, and it can't be until it's approved and a sponsor applies. The relevant context is that Lilly declined a PBS listing for tirzepatide in type 2 diabetes in April 2026 over price, and said it was difficult to see how a PBS listing for obesity could be secured under those conditions.

Is any weight-loss drug subsidised in Australia yet?

The PBAC recommended Wegovy for PBS listing in January 2026 for patients with established cardiovascular disease and a BMI of 35 or above, with price negotiations following the recommendation. That is a narrow eligibility gate rather than general obesity coverage.

When will retatrutide be available in Australia?

There's no announced date. Reporting indicates Lilly plans its first regulatory submission to the FDA in the first quarter of 2027; an Australian approval requires a separate TGA application and assessment after that.

Sources

This article is general information, not medical advice. Retatrutide is an investigational medicine and is not approved by the TGA for any use in Australia. Speak with a qualified Australian health professional about your own treatment. retatrutide.net.au is an independent information site and is not affiliated with, endorsed by or sponsored by Eli Lilly and Company.